Philadelphia is on track to record the lowest number of fatal overdoses in nearly a decade in 2025, according to preliminary state data.<\/p>\n
State officials reported 747 overdose deaths in the city as of Dec. 23. The city last recorded fewer than <\/b>1,000 deaths in 2016<\/a>, when 907 people died of overdoses.<\/p>\n The dramatic decline mirrors national trends in overdose deaths<\/a>, which peaked during the COVID-19 pandemic and have since been steadily falling. <\/p>\n Likewise, overdose deaths are dropping in Pennsylvania, with a 29% decline in deaths reported statewide between 2023 and 2024, according to preliminary data from the state. <\/p>\n Preliminary data for 2025 indicate that deaths are also on track to decline again across the state, with 2,178 overdoses reported as of Dec. 23, according to state data<\/a>. In all of 2024, the state recorded 3,340 overdose deaths<\/a>. <\/p>\n City officials in Philadelphia said there are slight differences in how the state and the city report overdose data and could not comment extensively on the state figures. But the city\u2019s own data also show dramatic drops in deaths in the last several years.<\/p>\n As recently as 2022, deaths in the city had soared to their highest-ever rate. But they decreased slightly in 2023. <\/p>\n Citing preliminary data from 2024, Philly Stat 360, a city-run database that tracks quality-of-life metrics, reported 1,064 overdose deaths \u2014 a 19% decrease in fatal overdoses from the year before. The city has not yet released its own statistics for 2025.<\/p>\n \u201cMy first reaction to hearing these numbers is absolute joy,\u201d said Keli McLoyd, the director of the Philadelphia Overdose Response Unit (ORU). \u201cWith that said, the number should be zero. Every overdose is preventable. Every single one of those lives lost is a person.\u201d<\/p>\n State officials said their work to expand overdose prevention efforts and ease entry to treatment has contributed to the dramatic drops in deaths. Still, they said, there is more work to be done.<\/p>\n \u201cEven with the overall decreases, we are still losing too many people \u2014 mothers, fathers, sons, daughters, grandparents, grandchildren \u2014 to overdose,\u201d said Stephany Dugan, a spokesperson for the Pennsylvania Department of Drug and Alcohol Programs. <\/p>\n She added that all Pennsylvanians \u201cdeserve equal and equitable access\u201d to addiction treatment.<\/p>\n Decreases in overdoses in Philadelphia<\/p>\n Discerning the cause of the dramatic drops in overdose deaths can be difficult, city officials say. <\/p>\n \u201cWe have to acknowledge that it\u2019s a huge, huge change, and so we really are hopefully doing something right. But I think it\u2019s going to be very hard, if not impossible, to say that one thing resulted in this massive reduction in fatal overdose deaths,\u201d McLoyd said. <\/p>\n Still, efforts at the state and local levels to increase access to naloxone, the overdose-reversing drug, likely made a difference, she said. <\/p>\n A number of local advocates in the addiction medicine field have speculated that there is still much to learn about how the COVID-19 pandemic affected overdose rates, said Daniel Teixeira da Silva, the director of the Division of Substance Use Prevention and Harm Reduction at the Philadelphia Department of Public Health.<\/p>\n \u201cWhen we look at the [overdose] increases after 2016, leading up to COVID, we can tie that to the introduction of fentanyl to the [drug] supply,\u201d he said Monday, referring to the synthetic opioid behind most of the city\u2019s fatal overdoses.<\/p>\n \u201cWhen you look at the increases from 2020 to 2022 \u2014 this is where I just don\u2019t think we know enough yet. It\u2019s hard to say COVID didn\u2019t impact [deaths]. We look at what was going on at the time, contributors to more risky substance use such as people losing employment, the isolation,\u201d Teixeira da Silva said.<\/p>\n Likewise, he said, policy changes that came about during the pandemic, such as easing some restrictions around opioid addiction medications, could be contributing to a drop in deaths now.<\/p>\n \u201cMaybe we\u2019re seeing benefits of the policies enacted during COVID,\u201d he said.<\/p>\n A changing drug landscape<\/p>\n On Philly Stat 360, city officials said fentanyl still drives nearly all of the opioid overdose deaths in the city. <\/p>\n But about 70% of deaths involved a stimulant like cocaine or methamphetamine in 2024. And about half of the city\u2019s fatal overdoses that year involved both stimulants and opioids.<\/p>\n Taking stock of the drop in overdose deaths, city officials noted the success of a 2024 program at the ORU to deliver naloxone, the opioid overdose-reversing drug sold under the brand name Narcan, to households in neighborhoods seeing a high number of overdoses. <\/p>\n They included neighborhoods in North Philadelphia<\/a>, where overdose deaths had risen over the last several years. Across the city, Black and Hispanic communities had seen high rises in overdoses \u2014 but neighbors often reported receiving fewer resources to address them. <\/p>\n Workers assigned to the naloxone initiative knocked on 100,000 doors offering the medication and access to addiction treatment. In some neighborhoods, up to 88% of neighbors who answered their doors accepted some kind of resource from staffers, according to a city report on the program<\/a>. McLoyd also helmed an effort to ensure all city fire stations had naloxone on hand. <\/p>\n \u201cWe\u2019re sharing those messages that this is a tool for everyone, not just people who use drugs or people who love those who use drugs,\u201d since some people may hide their addiction from others, she said.<\/p>\n This year, the city launched another campaign<\/a> to educate residents about the risk of heart disease from stimulant use. Eighty percent of overdose deaths among Black Philadelphians in 2023 involved a stimulant, and about half of the Black Philadelphians who died of an overdose between 2019 and 2022 had a history of cardiovascular disease.<\/p>\n \u201cWe see opioid-stimulant [overdose deaths] decreasing, but stimulant-only [overdoses] being really persistent,\u201d Teixeira da Silva said. \u201cStimulant overdoses are not reversed by Narcan,\u201d so it is important to help vulnerable residents understand the specific harms caused by stimulants.<\/p>\n As overdoses decrease in the general population, McLoyd said, it is crucial to maintain outreach efforts toward groups that have seen rising overdoses in recent years, like pregnant people<\/a> and teens in the juvenile justice system. <\/p>\n \u201cWithin certain populations, overdoses are still disproportionately high. We want to develop programs that speak specifically to those populations,\u201d she said.<\/p>\n City officials have also hailed the Riverview Wellness Center<\/a>, a 234-bed recovery home that offers supportive services to people who have completed a 30-day stay in inpatient treatment. <\/p>\n But Mayor Cherelle L. Parker<\/a>\u2019s administration has faced criticism from advocates for people in addiction over her decision last year <\/b>to slash funding for syringe exchanges<\/a>. Critics have also decried City Council legislation that regulates mobile medical services for people with addiction, requiring permits to offer care and limiting operating hours and locations in some neighborhoods<\/a>.<\/p>\n Teixeira da Silva said that the city is using the legislation to more effectively coordinate care for people with addiction. He said his division has been involved in the new permitting process for mobile services to \u201cget them approved as fast as possible to ensure there isn\u2019t a gap in access.\u201d<\/p>\n Statewide initiatives<\/p>\n Across Pennsylvania, the state\u2019s Overdose Prevention Program handed out more than 415,000 doses of naloxone in the first six months of 2025, said Dugan, the Pennsylvania Department of Drug and Alcohol Programs spokesperson. <\/p>\n Those doses helped reverse more than 6,100 overdoses, Dugan said earlier this month. <\/b><\/p>\n The state also distributed 437,000 test strips to help drug users detect fentanyl and xylazine. The animal tranquilizer contaminated much of Philadelphia\u2019s illicit opioid supply starting at the beginning of the decade and can cause severe skin wounds that sometimes lead to amputation.<\/p>\n Authorities credited efforts to increase access to treatment in rural counties and to decrease wait times for addiction treatment, implementing a \u201cwarm handoff\u201d program that allows patients to transfer directly from hospitals to addiction treatment.<\/p>\n More than 22,000 Pennsylvanians were offered addiction treatment from hospitals in the first 10 months of 2025. Nearly 60% of people who received referrals accepted them, state officials said.<\/p>\n Advocates say that the state\u2019s focus on programs to prevent overdoses has paid off. <\/p>\n \u201cI\u2019m really impressed and grateful for the state and their investment in harm-reduction programs,\u201d said Sarah Laurel, who heads the Philadelphia-based addiction outreach organization Savage Sisters.<\/p>\n But as the drug supply changes, she said, it is vital for health officials to collect more data on other harms of drug use besides overdoses. <\/p>\n For example, medetomidine, another powerful animal tranquilizer not approved for human use, has supplanted xylazine in Philadelphia\u2019s illicit opioid supply. <\/p>\n